8-K: Aligos Therapeutics: Phase 2 HBV Study Update & FDA Fast Track

Aligos Therapeutics announced positive interim results from its Phase 2 B-SUPREME study for pevifoscorvir sodium in chronic Hepatitis B, alongside FDA Fast Track Designation.

Summary

• Aligos Therapeutics has released initial results from the Phase 2 B-SUPREME study of pevifoscorvir sodium for chronic Hepatitis B virus (HBV) infection.
• The independent Data Safety Monitoring Review Board (DSMB) recommended continuing the study and increasing the sample size for the HBeAg- cohort to improve statistical power.
• Futility criteria for the HBeAg- cohort were not met.
• The study drug was well-tolerated by participants, with no observed viral breakthrough related to the study drugs.
• The U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to pevifoscorvir sodium, a potential best/first-in-class capsid assembly modulator (CAM-E) for HBV treatment.
• Enrollment completion for the HBeAg- cohort is anticipated in the second half of 2026, with topline data expected in 2027.
• The HBeAg- cohort currently has 74 participants enrolled, and the HBeAg+ cohort has 103 participants.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive development due to the DSMB recommendation to continue the study with increased sample size and the FDA Fast Track Designation, indicating progress and potential for the drug candidate.

Positives

• The DSMB recommended continuing the Phase 2 B-SUPREME study and increasing the sample size for the HBeAg- cohort to optimize statistical powering.
• Futility criteria for the HBeAg- cohort were not met, indicating potential efficacy.
• The study drug, pevifoscorvir sodium, was well-tolerated by participants with no clinically concerning safety signals.
• No viral breakthrough related to study drugs has been observed.
• The FDA granted Fast Track Designation to pevifoscorvir sodium, which can expedite development and review for serious conditions with unmet medical needs.
• The company expects to complete enrollment in the HBeAg- cohort in the second half of 2026, with topline data on track for 2027.

Negatives

• The DSMB recommended increasing the sample size for the HBeAg- cohort, suggesting that the current sample size may not be sufficient for optimal statistical powering.
• Enrollment in the HBeAg- cohort is ongoing, with completion expected in the second half of 2026, indicating the study is not yet fully enrolled.

Risks

• Risks and uncertainties inherent in the drug development process, including clinical trial design, conduct, and regulatory approval processes.
• The possibility that the planned increase in enrollment may not lead to success in meeting the study's primary endpoint.
• The potential for substantial risks and uncertainties that could cause actual results to differ materially from forward-looking statements.

Future Outlook

Topline data for the Phase 2 B-SUPREME study is expected in 2027, with guidance remaining unchanged. The company anticipates completing enrollment in the HBeAg- cohort in the second half of 2026 and expects the second interim analysis in the second half of 2026.

Management Comments

• "We are encouraged by this recommendation from the DSMB to increase the sample size in order to increase the probability for success of the study's primary endpoint," stated Lawrence Blatt, Ph.D., M.B.A., Chairman, President, and Chief Executive Officer at Aligos Therapeutics.
• "We believe we can enroll the necessary study participants in the coming months, with topline data on track for 2027."
• "Additionally, I am thrilled to share that pevifoscorvir sodium has been granted Fast Track Designation. Aligos mission since its founding has been to improve outcomes for patients with unmet needs in liver and viral diseases and being granted Fast Track Designation for pevifoscorvir sodium is the next step in our journey to make this a reality."
• "As we progress the Phase 2 B-SUPREME study, we look forward to working with regulators to determine the appropriate path forward."

Industry Context

StockSavvy.ai notes that the FDA Fast Track Designation for pevifoscorvir sodium highlights the significant unmet medical need in treating chronic Hepatitis B virus (HBV) infection. This designation, coupled with positive interim study results, suggests potential for Aligos Therapeutics to advance its candidate in a competitive landscape where new therapies are highly sought after.

Comparison to Industry Standards

• The B-SUPREME study is a randomized, double-blind, active-controlled multicenter study comparing pevifoscorvir sodium to tenofovir disoproxil fumarate, a standard of care in HBV treatment.
• The study aims for HBV DNA <LLOQ (10 IU/mL) as a primary endpoint, a common benchmark for antiviral efficacy in HBV treatment.
• Pevifoscorvir sodium's potential to achieve best/first-in-class status is benchmarked against existing therapies that often require long-term treatment and may not lead to functional cures.

Stakeholder Impact

• Shareholders: Potential positive impact on stock value if pevifoscorvir sodium successfully progresses through clinical trials and gains regulatory approval.
• Patients with Chronic HBV: Potential for a new, effective treatment option for a serious liver disease with significant unmet medical needs.
• Healthcare Providers: Introduction of a novel therapeutic agent for managing chronic HBV infection.

Next Steps

• Complete enrollment in the HBeAg- cohort of the Phase 2 B-SUPREME study (expected in the second half of 2026).
• Conduct the second interim analysis of the Phase 2 B-SUPREME study (expected in the second half of 2026).
• Report topline data from the Phase 2 B-SUPREME study (expected in 2027).
• Continue development of pevifoscorvir sodium, leveraging the FDA Fast Track Designation for expedited review and development.

Key Dates

Recommendation

The interim results are encouraging, and the FDA Fast Track Designation is a positive step. However, topline data is not expected until 2027, and the need to increase sample size suggests ongoing development and potential for unforeseen challenges. A 'hold' recommendation allows for further data to emerge before making a stronger investment decision.

Keywords

Aligos Therapeutics, pevifoscorvir sodium, Hepatitis B, HBV, Phase 2 Study, B-SUPREME, FDA Fast Track, Clinical Trial